Malignant melanoma in early Parkinson's disease: the DATATOP trial.
The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compared that to published expected values (N = 1.5) for a standard healthy population. The standardized event ratio was 3.3 (95% confidence interval, 1.1-7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma.
Constantinescu
Radu
R
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA. radu.constantinescu@ctcc.rochester.edu
Romer
Megan
M
Kieburtz
Karl
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D015994:Incidence; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000453:epidemiology*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology*; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000453:epidemiology*
D000978:Antiparkinson Agents; D007980:Levodopa